Correspondence 0001493152-24-043653 from Alteral Therapeutics ApS (CIK 0002026040)

Alteral Therapeutics ApS (CIK 0002026040)
Date: Nov. 5, 2024 · CIK: 0002026040 · Accession: 0001493152-24-043653

View on Edgar

AI Filing Summary & Sentiment

Referenced dates: September 23, 2024

Date

September 23, 2024

Author

/s/

Form

CORRESP

Company

Alteral Therapeutics ApS (CIK 0002026040)

Letter

Re: Alteral Therapeutics ApS—Comment Letter dated September 23, 2024

Bennett J. Yankowitz

Of Counsel

Yankowitz@SMCounsel.com

(424) 256-8560

November 5, 2024

Securities and Exchange Commission

Washington, D.C. 20549

Ladies and Gentlemen:

This letter responds to the comments made to Allan Traugott Wehnert, chief executive officer of Alteral Therapeutics ApS (the “Company”) in your letter of September 23, 2024 regarding the Company’s Schedule 13D filed with the Commission on June 5, 2024 (the “13D”). The numbered paragraphs below correspond to the numbered comments in your letter.

1. The delay in filing the 13D was inadvertent and due to the Company’s unfamiliarity with the requirements of the U.S. securities laws.

2. We have amended the disclosure in Item 2 of the 13D as requested.

3. We have amended the disclosure in Item 4 of the 13D as requested

The Company is filing an Amendment No.1 to the 13D concurrently with this letter.

Please let me know if you have any additional questions.

Sincerely,
/s/
Bennett J. Yankowitz

Show Raw Text

CORRESP
1
filename1.htm

Bennett
J. Yankowitz

Of
Counsel

Yankowitz@SMCounsel.com

(424)
256-8560

 November
5,  2024

Securities
and Exchange Commission

Washington,
D.C. 20549

    Re:
    Alteral
    Therapeutics ApS—Comment Letter dated September 23, 2024

Ladies
and Gentlemen:

This
letter responds to the comments made to Allan Traugott Wehnert, chief executive officer of Alteral Therapeutics ApS (the “Company”)
in your letter of September 23, 2024 regarding the Company’s Schedule 13D filed with the Commission on June 5, 2024 (the “13D”).
The numbered paragraphs below correspond to the numbered comments in your letter.

1. The
delay in filing the 13D was inadvertent and due to the Company’s unfamiliarity with the requirements of the U.S. securities laws.

2. We
have amended the disclosure in Item 2 of the 13D as requested.

3. We
have amended the disclosure in Item 4 of the 13D as requested

The
Company is filing an Amendment No.1 to the 13D concurrently with this letter.

Please
let me know if you have any additional questions.

    Sincerely,

    /s/
    Bennett J. Yankowitz

    Bennett
    J. Yankowitz

280
S. Beverly Dr., Suite 505 ●  Beverly Hills, California 90212

ShumakerMalloryLaw.com

SecProbe.io